Cardiovascular effects of pharmacologic therapies for smoking cessation

Journal of the American Society of Hypertension

Volumn 7, Issue 1, 2013, Pages 61-67

  Sobieraj, Diana M ^a   White, William B ^b,c   Baker, William L ^a,b  

^a UNIVERSITY OF CONNECTICUT   (United States)

^b UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

Author keywords

Bupropion; cardiovascular diseases; nicotine replacement; smoking cessation; tobacco use cessation products; varenicline

Indexed keywords

AMFEBUTAMONE; NICOTINE; NICOTINE GUM; NICOTINE LOZENGE; NICOTINE NASAL SPRAY; NICOTINE ORAL INHALER; NICOTINE PATCH; NICOTROLNS; PLACEBO; UNCLASSIFIED DRUG; VARENICLINE;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG MECHANISM; HUMAN; NICOTINE REPLACEMENT THERAPY; PRIORITY JOURNAL; REVIEW; SMOKING CESSATION; TOBACCO; TOBACCO DEPENDENCE;

DOPAMINE UPTAKE INHIBITORS; HUMANS; HYPERTENSION; NICOTINIC AGONISTS; RISK FACTORS; SMOKING; TOBACCO USE CESSATION PRODUCTS;

EID: 84872308544     PISSN: 19331711     EISSN: 18787436     Source Type: Journal    
DOI: 10.1016/j.jash.2012.11.003     Document Type: Review

References (52)

1. Smoking and tobacco use. Centers for Disease Control and Prevention. Available at: http://www.cdc.gov/tobacco/data-statistics/fact-sheets/health- effects/effects-cig-smoking/index.htm. Accessed August 24, 2012.
2. Statistical brief #7. Smoking status of adults - United States, 2000. Agency for Healthcare Research and Quality. Available at: http://meps.ahrq.gov/ mepsweb/data-files/publications/st7/stat07.shtml. Accessed August 24, 2012.
3. M.C. Fiore, C.R. Jean, and T.B. Baker Treating Tobacco Use and Dependence: 2008 Update. Clinical Practice Guideline 2008 Publish Health Service, US Department of Health and Human Services Rockville, MD
4. Working Group for the Study of Transdermal Nicotine in Patients with Coronary Artery Disease Nicotine replacement therapy for patients with coronary artery disease Arch Intern Med 154 1994 989 995
5. A.M. Joesph, S.M. Norman, L.H. Ferry, A.V. Prochazka, E.C. Westman, and B.G. Steele The safety of transdermal nicotine as an aid to smoking cessation in patients with cardiac disease N Engl J Med 335 1996 1792 1798
6. N.A. Rigotti, A.L. Pipe, N.L. Benowitz, C. Arteaga, D. Garza, and S. Tonstand Efficacy and safety of varenicline for smoking cessation in patients with cardiovascular disease: a randomized trial Circulation 121 2010 221 229
7. N.A. Rigotti, and K.A. Eagle Atrial fibrillation while chewing nicotine gum JAMA 255 1986 1018
8. A. Dacosta, J.M. Guy, B. Tardy, R. Gonthier, L. Denis, and M. Lamaud Eur Heart J 14 1993 1709 1711
9. J.R. Pierce Stroke following application of a nicotine patch Ann Pharmacother 28 1994 402
10. N.L. Benowitz, and S.G. Gourlay Cardiovascular toxicity of nicotine: implications for nicotine replacement therapy J Am Coll Cardiol 29 1997 1422 1431
11. N.L. Benowitz Cigarette smoking and cardiovascular disease: pathophysiology and implications for treatment Prog Cardiovasc Dis 46 2003 91 111
12. A.M. Joseph, and S.S. Fu Safety issues in pharmacotherapy for smoking in patients with cardiovascular disease Prog Cardiovasc Dis 45 2003 429 441
13. J.A. Ambrose, and R.S. Barua The pathophysiology of cigarette smoking and cardiovascular disease. An update J Am Coll Cardiol 43 2004 1731 1737
14. N.L. Benowitz Pharmacologic aspects of cigarette smoking and nicotine addiction N Engl J Med 319 1988 1318 1330
15. H.H. Mundal, P. Hjemdahl, and K. Ghesdal Acute effects of low dose nicotine gum on platelet function in non-smoking hypertensive and normotensive men Eur J Clin Pharmacol 41 1995 411 416
16. Z. Khoury, P. Comans, A. Keren, T. Lerer, A. Gavish, and D. Tzivoni Effects of transdermal nicotine patches on ambulatory ECK monitoring findings: A double-blind study in healthy smokers Cardiovasc Drugs Ther 10 1996 179 184
17. A.D. Blann, C. Steele, and C.N. McCollum The influence of smoking and of oral and transdermal nicotine on blood pressure, and haematology and coagulation indices Thromb Haemost 78 1997 1093 1096
18. J.J. Mahmarian, L.A. Moye, G.A. Nasser, S.F. Nagueh, M.F. Bloom, and N.L. Benowitz Nicotine patch therapy in smoking cessation reduces the extent of exercise-induced myocardial ischemia J Am Coll Cardiol 30 1997 125 130
19. S. Zevin, P. Jacob, and N.L. Benowitz Dose-related cardiovascular and endocrine effects of transdermal nicotine Clin Pharmacol Ther 64 1998 87 95
20. L. Fishbein, P. O'Brien, A. Hutson, D. Theriaque, P.W. Stacpoole, and T. Flotte Pharmacokinetics and pharmacodynamic effects of nicotine nasal spray devices on cardiovascular and pulmonary function J Investig Med 48 2000 435 440
21. J.E. Tanus-Santos, J.C.Y. Toledo, M. Cittadino, M. Sabha, J.C. Rocha, and H. Moreno Cardiovascular effects of transdermal nicotine in mildly hypertensive smokers Am J Hypertens 14 2001 610 614
22. N.L. Benowitz, and D.S. Sharp Inverse relationship between serum cotinine concentration and blood pressure in cigarette smokers Circulation 80 1989 1309 1312
23. N.L. Benowitz, A. Hansson, and P. Jacob Cardiovascular effects of nasal and transdermal nicotine and cigarette smoking Hypertension 39 2002 1107 1112
24. K.O. Haustein, J. Krause, H. Haustein, T. Rasmussen, and N. Cort Effects of cigarette smoking or nicotine replacement on cardiovascular risk factors and parameters of haemorheology J Int Med 252 2002 130 139
25. J.C. Yugar-Toledo, S.E. Ferreira-Melo, M. Sabha, E.A. Nogueira, O.R. Coelho, and J.F.M. Colombo Blood pressure circadian rhythm and endothelial function in heavy smokers: acute effects of transdermal nicotine J Clin Hypertens 7 2005 721 728
26. B. Najem, A. Houssiere, A. Pathak, C. Janssen, D. Lemogoum, and O. Xhaet Acute cardiovascular and sympathetic effects of nicotine replacement therapy Hypertension 47 2006 1162 1167
27. C. Martins, S.E. Ferreira-Melo, M. Sabha, O. Coelho, J.C. Yugar-Toledo, and T. Quinaglia Blood Press 18 2009 255 260
28. J.E. Tanus-Santos, R.C. Sampaio, S. Hyslop, K.G. Franchini, and H. Moreno Endothelin ET(A) receptor antagonism attenuates the pressor effects of nicotine in rats Eur J Pharmacol 396 2000 33 37
29. S.E. Kimmel, J.A. Berlin, C. Miles, J. Jaskowiak, J.L. Carson, and B.L. Strom Risk of acute first myocardial infarction and use of nicotine patches in the general population J Am Coll Cardiol 37 2001 1297 1302
30. S. Greenland, M.H. Satterfield, and S.F. Lanes A meta-analysis to assess the incidence of adverse effects associated with the transdermal nicotine patch Drug Safety 18 1998 297 308
31. T.J. Meine, M.R. Patel, J.B. Washam, P.A. Pappas, and J.G. Jollis Safety and effectiveness of transdermal nicotine patch in smokers admitted with acute coronary syndromes Am J Cardiol 95 2005 976 978
32. K.J. Woold, M.N. Zabad, J.M. Post, S. McNitt, G.C. Williams, and J.D. Bisognano Effect of nicotine replacement therapy on cardiovascular outcomes after acute coronary syndromes Am J Cardiol 2012 June 20 [Epub ahead of print]
33. Zyban Package Insert. Available at: http://www.accessdata.fda.gov/ drugsatfda-docs/label/2012/020711s036lbl.pdf. Accessed August 15, 2012.
34. R. Richmond, and N. Zwar Review of bupropion for smoking cessation Drug Alcohol Rev 22 2003 203 220
35. S.P. Roose, A.H. Glassman, and E.G.V. Giardina Cardiovascular effects of imipramine and bupropion in depressed patients with congestive heart failure J Clin Psychcopharmacol 7 1987 247 251
36. S.P. Roose, G.W. Dalack, and A.H. Glassman Cardiovascular effects of bupropion in depressed patients with heart disease Am J Psychiatry 148 1991 512 516
37. E.C. Settle, S.M. Stahl, and S.R. Batey Safety profile of sustained-release bupropion in depression: results of three clinical trials Clin Ther 21 1999 454 463
38. N.A. Rigotti, A.N. Thorndike, and S. Regan Bupropion for smokers hospitalized with acute cardiovascular disease Am J Med 119 2006 1080 1087
39. S. Tonstad, C. Farsang, and G. Klaene Bupropion SR for smoking cessation in smokers with cardiovascular disease: a multicenter randomized study Eur Heart J 24 2003 946 955
40. D. Planer, I. Lev, and Y. Elitzur Bupropion for smoking cessation in patients with acute coronary syndrome Arch Intern Med 171 2011 1055 1060
41. M.E. Thase, B.R. Haight, and M.C. Johnson A randomized, double-blind, placebo-controlled study of the effects of sustained-release bupropion on blood pressure in individuals with mild untreated hypertension J Clin Psychopharmacol 28 2008 302 307
42. Chantix. Package Insert. Available at http://www.accessdata.fda.gov/ drugsatfda-docs/label/2012/021928s028lbl.pdf. Accessed August 6, 2012.
43. H. Rollema, L.K. Chambers, and J.W. Coe Pharmacological profile of the alpha4beta2 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid Neuropharmacology 52 2007 985 994
44. K.B. Mihalak, F.I. Carroll, and C.W. Luetje Varenicline is a partial agonist at alpha4beta2 and a full agonist at alpha7 neuronal nicotinic receptors Molecular Pharmacol 70 2006 801 805
45. H. Ari, N. Celiloglu, S. Ari, S. Cosar, K. Doganay, and T. Bozat The effect of varenicline on heart rate variability in healthy smokers and nonsmokers Autonom Neurosci Basic Clin 164 2011 82 86
46. J. Wang, X. Wang, and M. Irnaten Endogenous acetylcholine and nicotine activation enhances gabaergic and glycinergic inputs to cardiac vagal neurons J Neurophysiol 89 2003 2473 2481
47. D. Gonzales, S.I. Rennard, and M. Nides Varenicline, an alpha4beta2 nicotine acetylcholine receptor partial agonist, vs sustained release bupropion and placebo for smoking cessation JAMA 296 2006 47 55
48. D.E. Jorenby, J.T. Hays, and N.A. Rigottie Efficacy of varenicline an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation JAMA 296 2006 56 63
49. S. Tonstand, P. Tonnesen, P. Hajek, K.E. Williams, C.B. Cillings, and K.R. Reeves Effect of maintenance therapy with varenicline on smoking cessation JAMA 296 2006 64 71
50. Food and Drug Administration Safety Communication. Chantix (varenicline) may increase the risk of certain cardiovascular adverse events in patients with cardiovascular disease. Available at: http://www.fda.gov/Drugs/Drugsafety/ ucm259161.htm. (Accessed August 6, 2012).
51. S. Singh, Y.K. Loke, J.G. Spangler, and C.D. Furberg Risk of serious adverse cardiovascular events associated with varenicline: a systematic review and meta-analysis CMAJ 183 2011 1359 1366
52. J.J. Prochaska, and J.F. Hilton Risk of cardiovascular serious adverse events associated with varenicline use for tobacco cessation: systematic review and meta-analysis BMJ 344 2012 e2856